HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

HBW Legislative News: Another Federal CR, Michigan On DXM List, Senators Say Supplements Are 'Medical Expenses'

Executive Summary

Federal agencies at FY 2019 funding for another month; Michigan imposes age restriction on OTC DXM sales; and senators urge IRS to make supplements 'medical expenses'.

You may also be interested in...



$2m For CBD Policy In FDA Budget, But No Directive On Setting Safe Level

Both Senate and House reports on FDA FY 2020 appropriation include requests for agency’s research, policy evaluation, market surveillance, issuance of an enforcement discretion policy and appropriate regulatory activities related to regulated products that contain hemp-derived CBD. House report, though, expresses stronger concern about exploding sales of potentially unsafe CBD supplements.

House Members Suggest Buying Some Supplements With Pre-Tax Savings

Eight GOP House members urge IRS to allow supplements labeled with approved health claims to be considered “medical expenses” eligible for payment with pre-tax health savings accounts beginning with tax year 2020.

No Shutdown But Funding Lower Than House Bill In US FDA Budget Forecast

Former Senate Appropriations Committee staffer expects FDA's FY 2020 budget will not be finalized until early next year and that it will be close to the sum in the appropriations bill passed by the Senate.

Related Content

Topics

UsernamePublicRestriction

Register

LL1134043

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel